Alder BioPharmaceuticals, Inc.
Corporate Headquarters
11804 North Creek Parkway South
Bothell
Washington
98011
United States
Tel: 425-205-2900
Fax: 425-205-2901
Website: http://www.alderbio.com/
Email: hr@alderbio.com
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention.
Stock Symbol: ALDR
Stock Exchange: NASDAQ
119 articles about Alder BioPharmaceuticals, Inc.
-
Alder Biopharmaceuticals Inc. Announces Addition To NASDAQ Biotechnology Index
12/17/2014
-
Alder Biopharmaceuticals Inc. To Present At 26th Annual Piper Jaffray Healthcare Conference
11/26/2014
-
Alder Biopharmaceuticals Inc. Release: Data From Phase 2b Clinical Trial Of Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Active Psoriatic Arthritis, To Be Presented At The American College of Rheumatology Annual Meeting
11/17/2014
-
Alder Biopharmaceuticals Inc. To Present At Credit Suisse 2014 Healthcare Conference
11/4/2014
-
Alder Biopharmaceuticals Inc. Reports Third Quarter 2014 Financial And Operating Results
11/4/2014
-
Alder Biopharmaceuticals Inc. Initiates Phase 2b Clinical Trial Of ALD403 For Preventative Treatment Of Chronic Migraine
11/4/2014
-
Alder Biopharmaceuticals Inc. To Host Conference Call To Discuss Third Quarter 2014 Financial And Operating Results
10/24/2014
-
Data From Alder Biopharmaceuticals Inc.' Proof-Of-Concept Clinical Trial Of ALD403 Published In Lancet Neurology Demonstrates ALD403 Effective In The Preventive Treatment Of Migraine
10/6/2014
-
Bristol-Myers Squibb Company Gives Back Rights To Alder Biopharmaceuticals Inc.'s Promising Arthritis Drug Clazakizumab
9/2/2014
-
Alder Biopharmaceuticals Inc. Reports Second Quarter 2014 Financial And Operating Results
8/5/2014
-
Alder Biopharmaceuticals Inc. To Host Conference Call To Discuss Second Quarter 2014 Financial And Operating Results
7/29/2014
-
Alder Biopharmaceuticals Inc. Added to Russell 3000® Index
6/27/2014
-
Alder Biopharmaceuticals Inc. Release: Data From Proof-Of-Concept Clinical Trial Of ALD403, A Monoclonal Antibody Against CGRP For The Prevention Of Migraine, To Be Presented At 56th Annual Scientific Meeting Of The American Headache Society
6/26/2014
-
Alder Biopharmaceuticals Inc. Reports First Quarter 2014 Financial Results
6/19/2014
-
Alder Biopharmaceuticals Inc. To Present At Two Conferences In June
6/11/2014
-
Biotech IPO Slump Continues as Alder Biopharmaceuticals Inc. Prices Below Range
5/8/2014
-
Seattle Biotech Alder Biopharmaceuticals Inc. Files For A $115 Million IPO
3/19/2014
-
Bristol-Myers Squibb Company, Alder Biopharmaceuticals Inc.'s Rheumatoid Arthritis Drug Passes Key Test, Causes Stir at Huge Conference
11/4/2013
-
First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Inc.' Lead Therapeutic Candidate for Treatment of Migraine, ALD403
3/20/2013
-
Alder Biopharmaceuticals Inc. Receives $3.5 Million Milestone Payment From Bristol-Myers Squibb Company for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohn's Disease
8/27/2012